Founding Member
Albert Bourla, DVM, PhD
Chief Executive Officer
Albert Bourla became Chief Executive Officer on January 1, 2019.
In his previous role, Albert was Pfizer’s Chief Operating Officer (COO), overseeing the company’s commercial strategy, manufacturing and global product development functions. Prior to being named COO, Albert was the Group President of Pfizer Innovative Health, responsible for the Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines and Consumer Healthcare business groups. He also created the Patient and Health Impact group, dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations and ensuring broader business model innovation.
Albert has more than 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines, including Group President of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare business and President and General Manager of Pfizer’s Established Products business.
Albert joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East, and in 2009, he assumed additional responsibilities for Asia and Pacific.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the Board of Directors of Pfizer Inc., the Pfizer Foundation and the Partnership for New York City.
CEO Cancer Gold Standard™
Gold Standard Employer
Since 2008
At Pfizer we are committed to wellness through helping colleagues and patients find treatments and cures, and advancing the goal of preventing illness. The CEO Cancer Gold Standard is one way to help colleagues and their family members take responsibility for their health.
Albert Bourla, DVM, PhD
Gold Standard Task force Participation
Task Force Member(s): Nicole Shaffer, DNP, CRNP-BC, COHN-S, FAAO, Director, Occupational Health & Wellness
Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Mace L. Rothenberg, MD, Chief Development Officer for Oncology, Global Product Development Group, Pfizer
Project Data Sphere, LLC
an independent initiative of the Life Sciences Consortium
Data Provider
Pfizer, Inc.
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer’s disease and cancer.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
